Mustang Leads Fortress's CAR-T Ambitions Of Monstrous Proportions
Emerging Company Profile: The two-year-old company combines the Fortress Biotech model with City of Hope's broad expertise in CAR-T technology, plus leadership from a pioneer in the space.
You may also be interested in...
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.
IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.